SWKHL

SWK Holdings Corporation is engaged in specialty finance and asset management business. The Company’s segments include Finance Receivables and Pharmaceutical Development. Finance Receivables segment is a healthcare capital provider, which offers customized financing solutions to a range of life science companies, institutions, and inventors. This segment is primarily focused on monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Its Pharmaceutical Development segment operates through its subsidiary Enteris BioPharma, Inc. (Enteris). Enteris is a clinical development and manufacturing organization providing development services to pharmaceutical partners as well as innovative formulation solutions built around its oral drug delivery technologies, the Peptelligence platform.

Wall Street analysts forecast SWKHL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SWKHL is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

SWK Holdings Corp revenue for the last quarter amounts to NaN USD, decreased % YoY.

SWK Holdings Corp. EPS for the last quarter amounts to USD, decreased % YoY.

SWK Holdings Corp (SWKHL) has 0 emplpoyees as of January 05 2026.

Today SWKHL has the market capitalization of 0.00 USD.